Positions

Overview

  • Dr. Acosta Lara received her initial medical training at Universidad Autónoma de Tamaulipas with her internship and residency completed at University of Texas Medical Branch. Dr. Acosta Lara served as Chief Resident at the University of Texas Medical Branch after completing her residency training. Dr. Acosta Lara began a clinical and research fellowship at UAB in 2013. Following her fellowship, she joined the UAB faculty in July 2016 as Assistant Professor

    • Research Overview

  • Dr. Acosta Lara's research and clinical interests relate to interstitial lung diseases with a particular interest those related to connective tissue diseases. Dr. Acosta has published and presented work on interstitial lung diseases, sarcoidosis and oxidative stress.

    • Principal Investigator On

  • Private Grant  awarded by RESPIVANT SCIENCES, GMBH 2019 - 2022

    • Investigator On

  • Private Grant  awarded by GENKYOTEX SA 2020 - 2025
  • Private Grant  awarded by ATYR PHARMA, INC. 2019 - 2024
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2018 - 2024
  • Private Grant  awarded by FIBROGEN, INC. 2020 - 2023
  • Private Grant  awarded by PRIME EDUCATION LLC 2020 - 2023
  • Private Grant  awarded by GALAPAGOS NV. 2020 - 2023
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD 2019 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by MALLINCKRODT ARD, INC 2018 - 2021
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018 - 2021
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2018 - 2020
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2020
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University 2019 - 2020
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh 2017 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh 2018 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary FibrosiCleanUP-IPF  awarded by Weill (Joan and Sanford I.) Medical College of Cornell University 2018 - 2019
  • Private Grant  awarded by CELGENE CORPORATION 2018 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2019
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2015 - 2018
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2018
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2017

    • Education And Training

  • University of Texas Medical Branch at Galveston, Residency
  • University of Alabama at Birmingham Pulmonary, Allergy, and Critical Care Medicine, Postdoctoral Fellowship
  • Doctor of Medicine, Autonomous University of Tamaulipas 2006

    • Full Name

  • Maria Acosta Lara